MetaCap

Maze Therapeutics (MAZE) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Maze Therapeutics is the larger company by market cap ($1.72 billion vs $1.45 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MAZE-8.62%WWB-14.79%
+7%-8%-22%
Nov 13, 20261 yearNov 20, 2026
MAZE-8.62%WWB-14.79%
+1%-7%-16%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MAZE versus WWB key metrics
MetricMAZEWWB
Share price$31.37$24.29
Market cap$1.72B$1.45B
1-day change-3.27%+1.15%
YTD return-24.28%—
1-year return-13.49%—
EPS (TTM)$-2.62$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-131.12M—
52-week high$53.65$33.99
52-week low$21.95$18.35
Distance from 52-week high-41.53%-28.55%
Analyst consensusstrong_buy—
Avg. price target upside+99.11%—
Average volume737.14K434.33K
Shares outstanding54.68M59.58M
Employees14133
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Maze Therapeutics

MAZE stock →

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

MAZE vs WWB FAQ

Which is bigger, Maze Therapeutics or Windward Bio Group?

Maze Therapeutics (MAZE) is larger, with a market capitalization of $1.72B compared with $1.45B for Windward Bio Group (WWB).

Are Maze Therapeutics and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons